Idiopathic Pulmonary Fibrosis

Latest News

ILD | Image Credit: PH alex aviles - stock.adobe.com
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

November 20th 2024

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

ISM001-055 is a novel drug developed through generative AI biotechnology | image credit: ipopba - stock.adobe.com
Novel, AI-Procured ISM001-055 Demonstrates Great Promise for Treatment of IPF

November 12th 2024

AJMC Q&A with Dr Maria Padilla | Background image credit: ipopba - stock.adobe.com
Key ILD Topics at Mount Sinai’s Advances in Pulmonary Medicine 2024

November 5th 2024

IPF written on whiteboard| Image Credit: Vitalii Vodolazskyi - stock.adobe.com
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist

October 30th 2024

ILD spelled out with wooden blocks | Image Credit: PH alex aviles - stock.adobe.com
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD

October 21st 2024

Unmet Needs and Future Treatments of Idiopathic Pulmonary Fibrosis

Learn about the current standard of care for patients with idiopathic pulmonary fibrosis (IPF), including considerations for treatment regimens, disease progression, clinical and economic impact of IPF, and the future of IPF therapies.

Watch the latest AJMC Insights on Idiopathic Pulmonary Fibrosis (IPF).

More News

Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis
June 5th 2020

Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis

Rachel Lutz
The study sought to determine whether patient-reported outcomes are linked with death beyond clinical risk factors in patients with idiopathic pulmonary fibrosis (IPF).
Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds
January 25th 2020

Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds

Alison Rodriguez
Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.
Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis
January 17th 2020

Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis

Matthew Gavidia
Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.
Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF
May 18th 2019

Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF

Samantha DiGrande
In a study to be presented at the American Thoracic Society (ATS) Annual Meeting, held in Dallas, Texas on May 17-22, 2019, researchers investigated visit-to-visit variability in the forced vital capacity (FVC) of patients with idiopathic pulmonary fibrosis (IPF).
Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF
May 10th 2019

Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF

Samantha DiGrande
During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet) in the treatment of idiopathic pulmonary fibrosis (IPF) in a real-world setting.
<12

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo